Ginsenocide Rb1: A novel Anti-Obesity and Anti-Hyperglycemic Compound
人参皂苷 Rb1:一种新型抗肥胖和抗高血糖化合物
基本信息
- 批准号:8295114
- 负责人:
- 金额:$ 32.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdipose tissueAdverse effectsAlternative MedicineAntidiabetic DrugsAreaAsiansBlood - brain barrier anatomyBlood GlucoseBody WeightBrainBrain regionChronicChronic DiseaseClinicalClinical ResearchClinical TrialsComplexCountryDataDiabetes MellitusDietDoseEatingEpidemicFOS geneFastingFatty acid glycerol estersFutureGinseng PreparationHomeostasisHumanHyperglycemiaHypothalamic structureIncidenceIntraperitoneal InjectionsKnowledgeLeptinLeptin resistanceMediatingMedicineMetabolic DiseasesMetabolic syndromeMiddle HypothalamusNeuronsNeuropeptidesNon-Insulin-Dependent Diabetes MellitusNucleus solitariusObesityPeripheralPersonal SatisfactionPharmaceutical PreparationsPreventionPropertyPublic HealthRat-1RattusRegulationReportingResearchResistanceRodentRoleSafetySatiationSignal PathwaySignal TransductionSiteStagingSymptomsTestingTherapeuticTissuesToxic effectTraditional MedicineTranslatingUnited StatesWeight GainWorkbaseblood glucose regulationdesignfasting glucosefeedingginsenoside Rb1glucose metabolismimpaired glucose toleranceimprovedinnovationinsulin secretioninsulin sensitivityintraperitonealleptin receptornovelobesity treatmentpreclinical studypreventresponse
项目摘要
DESCRIPTION (provided by applicant): Obesity and type-2 diabetes are national and worldwide epidemics. Since currently available anti-obesity and anti-diabetes drugs have limited efficacy as well as safety concerns, identifying new target compounds, particularly with dual properties in controlling both body weight and blood glucose, is a high priority. Recently, we have identified novel functions of ginsenoside Rb1 (Rb1), the most abundant and biologically active compound in ginseng. Ginseng has been used as a traditional crude medicine in Asian countries to restore and enhance well-being without notable toxic side effects for thousands of years, and is one of the best-selling herbal supplements in the United States. Peripheral administration of Rb1 to rats potently suppresses food intake without eliciting signs of toxicity. Chronic treatment with Rb1 significantly reduces food intake and body weight gain in high-fat diet (HFD)-induced obese rats and also significantly decreases fasting blood glucose and improves impaired glucose tolerance to a greater extent than what occurs in pair-fed controls. These results demonstrate potential novel roles for Rb1 as an anti-obesity and anti-hyperglycemic agent. Our central hypothesis is that Rb1 increases leptin sensitivity to maintain body energy and glucose homeostasis, and it is strongly supported by our preliminary data in lean and HFD-induced obese rats. The rationale for the proposed research is that once the particular mechanisms of Rb1 in the regulation of body weight and blood glucose are understood, the newly acquired information will allow rational design of future pre-clinical studies and clinical trials to develop Rb1 as a novel agent for the prevention and treatment of obesity and diabetes. Guided by strong preliminary data, we propose testing this hypothesis by pursuing three specific aims. First, to determine the interaction of Rb1 and leptin in reducing food intake in rats. Second, to identify the mechanisms through which Rb1 improves energy homeostasis in HFD-induced obese rats. Third, to test the hypothesis that Rb1, like leptin, regulates glucose metabolism by increasing insulin sensitivity at peripheral tissues and/or by increasing insulin secretion. The proposed work is innovative because it assesses novel pharmacological functions of Rb1 in the regulation of energy and glucose homeostasis. Successful completion of the proposed research will enhance our understanding of the mechanisms by which Rb1 prevents and treats obesity and associated symptoms of the metabolic syndrome. Given the continuing epidemics of obesity and diabetes, identifying and understanding a novel pharmacological agent, such as Rb1, with the dual properties of controlling body weight and reducing blood glucose, is expected to have a significant public health impact.
PUBLIC HEALTH RELEVANCE: The objective of this project is to elucidate the mechanisms by which the compound Rb1 prevents and treats obesity, diabetes and other symptoms of the metabolic syndrome. Given the growing incidence of obesity and diabetes, identifying and understanding a new pharmacological agent, like Rb1, with dual properties of controlling body weight and reducing blood glucose, is expected to have a significant public health impact.
描述(由申请人提供):肥胖和2型糖尿病是国家和世界范围的流行病。由于目前可用的抗肥胖和抗糖尿病药物具有有限的功效以及安全性问题,因此鉴定新的目标化合物,特别是具有控制体重和血糖的双重性质的目标化合物是高度优先的。最近,我们已经确定了人参中最丰富和最具生物活性的化合物Rb 1(Rb 1)的新功能。几千年来,人参一直被用作亚洲国家的传统生药,以恢复和增强健康,而没有明显的毒副作用,并且是美国最畅销的草药补充剂之一。大鼠外周给予Rb 1可有效抑制食物摄入,而不会引起毒性体征。长期治疗与Rb 1显着减少食物摄入量和体重增加高脂饮食(HFD)诱导的肥胖大鼠,也显着降低空腹血糖和改善葡萄糖耐量受损的程度比发生在配对喂养的控制。这些结果表明Rb 1作为抗肥胖和抗高血糖剂的潜在新作用。我们的中心假设是,Rb 1增加瘦素的敏感性,以维持身体能量和葡萄糖的稳态,这是强烈支持我们的初步数据在瘦和HFD诱导的肥胖大鼠。这项研究的基本原理是,一旦了解了Rb 1调节体重和血糖的特定机制,新获得的信息将允许合理设计未来的临床前研究和临床试验,以开发Rb 1作为预防和治疗肥胖和糖尿病的新型药物。在强有力的初步数据的指导下,我们提出通过追求三个具体目标来检验这一假设。首先,确定Rb 1和瘦素在减少大鼠摄食量中的相互作用。第二,确定Rb 1改善HFD诱导的肥胖大鼠能量稳态的机制。第三,检验Rb 1和瘦素一样,通过增加外周组织的胰岛素敏感性和/或通过增加胰岛素分泌来调节葡萄糖代谢的假设。这项工作是创新的,因为它评估了Rb 1在调节能量和葡萄糖稳态方面的新药理学功能。成功完成拟议的研究将提高我们对Rb 1预防和治疗肥胖和代谢综合征相关症状的机制的理解。鉴于肥胖症和糖尿病的持续流行,识别和理解具有控制体重和降低血糖双重特性的新型药理学试剂,如Rb 1,预计将对公共卫生产生重大影响。
公共卫生相关性:该项目的目的是阐明化合物Rb 1预防和治疗肥胖、糖尿病和代谢综合征的其他症状的机制。鉴于肥胖和糖尿病的发病率不断增加,识别和了解一种新的药理学药物,如Rb 1,具有控制体重和降低血糖的双重特性,预计将对公共卫生产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Min Liu其他文献
Min Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Min Liu', 18)}}的其他基金
Role of the GI lymphatic system in hormonal signaling and nutrient metabolism
胃肠道淋巴系统在激素信号传导和营养代谢中的作用
- 批准号:
10164765 - 财政年份:2018
- 资助金额:
$ 32.97万 - 项目类别:
Role of the GI lymphatic system in hormonal signaling and nutrient metabolism
胃肠道淋巴系统在激素信号传导和营养代谢中的作用
- 批准号:
10405039 - 财政年份:2018
- 资助金额:
$ 32.97万 - 项目类别:
Smarter exosomes derived from engineered MSCs promote neo-vascularization
源自工程化 MSC 的更智能的外泌体可促进新血管形成
- 批准号:
10078974 - 财政年份:2018
- 资助金额:
$ 32.97万 - 项目类别:
Role of the GI lymphatic system in hormonal signaling and nutrient metabolism
胃肠道淋巴系统在激素信号传导和营养代谢中的作用
- 批准号:
9789261 - 财政年份:2018
- 资助金额:
$ 32.97万 - 项目类别:
Ginsenocide Rb1: A Novel Anti-Obesity and Anti-Hyperglycemic Compound
人参皂苷 Rb1:一种新型抗肥胖和抗高血糖化合物
- 批准号:
8996168 - 财政年份:2012
- 资助金额:
$ 32.97万 - 项目类别:
Ginsenocide Rb1: A Novel Anti-Obesity and Anti-Hyperglycemic Compound
人参皂苷 Rb1:一种新型抗肥胖和抗高血糖化合物
- 批准号:
8451332 - 财政年份:2012
- 资助金额:
$ 32.97万 - 项目类别:
Ginsenocide Rb1: A Novel Anti-Obesity and Anti-Hyperglycemic Compound
人参皂苷 Rb1:一种新型抗肥胖和抗高血糖化合物
- 批准号:
8788261 - 财政年份:2012
- 资助金额:
$ 32.97万 - 项目类别:
Ginsenocide Rb1: A Novel Anti-Obesity and Anti-Hyperglycemic Compound
人参皂苷 Rb1:一种新型抗肥胖和抗高血糖化合物
- 批准号:
8599713 - 财政年份:2012
- 资助金额:
$ 32.97万 - 项目类别:
Brain apoA-IV Mediates Estrogenic Reduction of Dietary Obesity in Female Rats
脑 apoA-IV 介导雌激素减少雌性大鼠饮食肥胖
- 批准号:
8306045 - 财政年份:2011
- 资助金额:
$ 32.97万 - 项目类别:
Brain apoA-IV mediates estrogenic reduction of dietary obesity in female rats
脑apoA-IV介导雌性大鼠雌激素减少饮食肥胖
- 批准号:
8163309 - 财政年份:2011
- 资助金额:
$ 32.97万 - 项目类别:
相似海外基金
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
$ 32.97万 - 项目类别:
Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
- 批准号:
BB/Y006542/1 - 财政年份:2024
- 资助金额:
$ 32.97万 - 项目类别:
Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
- 批准号:
23H03323 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
- 批准号:
23K08293 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
- 批准号:
479570 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
- 批准号:
488898 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
- 批准号:
23K19922 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
- 批准号:
10605981 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
- 批准号:
10604611 - 财政年份:2023
- 资助金额:
$ 32.97万 - 项目类别: